FOLD RSI Chart
Last 7 days
3.8%
Last 30 days
-9.2%
Last 90 days
-30.4%
Trailing 12 Months
-16.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 423.5M | 0 | 0 | 0 |
2023 | 336.8M | 350.6M | 372.4M | 399.4M |
2022 | 317.8M | 321.1M | 323.3M | 329.2M |
2021 | 266.8M | 281.8M | 293.9M | 305.5M |
2020 | 208.7M | 226.9M | 245.6M | 260.9M |
2019 | 108.6M | 131.4M | 159.6M | 182.2M |
2018 | 49.5M | 63.6M | 73.3M | 91.2M |
2017 | 9.1M | 16.3M | 25.0M | 36.9M |
2016 | 0 | 0 | 2.9M | 5.3M |
2014 | 11.5M | 8.1M | 4.7M | 1.2M |
2013 | 0 | 0 | 0 | 15.0M |
2012 | 23.2M | 29.8M | 24.0M | 18.4M |
2011 | 47.2M | 38.6M | 30.0M | 21.4M |
2010 | 0 | 0 | 0 | 55.8M |
2009 | 0 | 0 | 0 | 64.4M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | campbell bradley l | acquired | 64,575 | 8.61 | 7,500 | president and ceo |
May 01, 2024 | campbell bradley l | sold | -75,523 | 10.0698 | -7,500 | president and ceo |
Apr 15, 2024 | prout samantha | sold (taxes) | -74,907 | 10.66 | -7,027 | chief accounting officer |
Apr 01, 2024 | campbell bradley l | acquired | 64,575 | 8.61 | 7,500 | president and ceo |
Apr 01, 2024 | campbell bradley l | sold | -87,495 | 11.6661 | -7,500 | president and ceo |
Mar 15, 2024 | campbell bradley l | sold (taxes) | -153,545 | 11.48 | -13,375 | president and ceo |
Mar 07, 2024 | sblendorio glenn | acquired | 42,000 | 2.8 | 15,000 | - |
Mar 05, 2024 | mcglynn margaret g | acquired | 21,000 | 2.8 | 7,500 | - |
Mar 05, 2024 | raab michael | acquired | 42,000 | 2.8 | 15,000 | - |
Mar 05, 2024 | mcglynn margaret g | sold | -100,500 | 13.4 | -7,500 | - |
Which funds bought or sold FOLD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | reduced | -50.07 | -16,835,300 | 11,918,700 | 0.30% |
May 16, 2024 | COMERICA BANK | reduced | -9.23 | -361,666 | 1,105,840 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -3.96 | -686,877 | 2,701,840 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -43.82 | -1,986,520 | 1,735,980 | -% |
May 16, 2024 | Ancora Advisors LLC | unchanged | - | -6,493 | 31,735 | -% |
May 15, 2024 | ORBIMED ADVISORS LLC | reduced | -29.24 | -4,719,010 | 6,718,130 | 0.12% |
May 15, 2024 | Squarepoint Ops LLC | new | - | 2,958,030 | 2,958,030 | -% |
May 15, 2024 | Integrated Wealth Concepts LLC | added | 0.2 | -46,989 | 229,290 | -% |
May 15, 2024 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | new | - | 194,240 | 194,240 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -91.58 | -353,070 | 26,540 | -% |
Unveiling Amicus Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Amicus Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Amicus Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -4.1% | 110,403,000 | 115,082,000 | 103,501,000 | 94,503,000 | 86,270,000 | 88,096,000 | 81,691,000 | 80,731,000 | 78,715,000 | 82,154,000 | 79,545,000 | 77,413,000 | 66,402,000 | 70,571,000 | 67,437,000 | 62,353,000 | 60,525,000 | 55,293,000 | 48,768,000 | 44,130,000 | 34,046,000 |
Gross Profit | -6.7% | 96,836,000 | 103,758,000 | 93,555,000 | 85,389,000 | 79,328,000 | 78,712,000 | 68,255,000 | 72,534,000 | 71,133,000 | 74,303,000 | 67,849,000 | 69,033,000 | 59,863,000 | 61,154,000 | 59,038,000 | 55,677,000 | 53,973,000 | 48,348,000 | 43,172,000 | 38,763,000 | 29,991,000 |
Operating Expenses | 15.9% | 124,557,000 | 107,450,000 | 110,578,000 | 104,249,000 | 116,964,000 | 121,040,000 | 102,095,000 | 133,147,000 | 146,472,000 | 146,449,000 | 110,248,000 | 107,867,000 | 112,918,000 | 125,989,000 | 111,799,000 | 107,022,000 | 132,030,000 | 137,371,000 | 100,477,000 | 115,193,000 | 111,270,000 |
S&GA Expenses | 25.3% | 88,029,000 | 70,239,000 | 65,651,000 | 65,423,000 | 73,957,000 | 54,274,000 | 47,272,000 | 53,379,000 | 58,116,000 | 57,601,000 | 46,107,000 | 42,276,000 | 46,726,000 | 43,685,000 | 37,850,000 | 34,657,000 | 40,215,000 | 43,300,000 | 39,680,000 | 42,578,000 | 44,303,000 |
EBITDA Margin | 17.1% | -0.19 | -0.23 | -0.36 | -0.40 | -0.50 | -0.61 | -0.66 | -0.73 | -0.69 | -0.66 | -0.66 | -0.74 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -3.0% | 12,436,000 | 12,827,000 | 12,986,000 | 12,492,000 | 11,844,000 | 11,095,000 | 9,620,000 | 8,257,000 | 8,147,000 | 8,164,000 | 8,165,000 | 8,150,000 | 7,992,000 | 8,277,000 | 6,784,000 | 3,635,000 | 3,729,000 | 3,767,000 | 4,026,000 | 4,625,000 | 6,454,000 |
Income Taxes | 121.5% | 4,836,000 | 2,183,000 | -3,128,000 | 2,715,000 | -287,000 | -14,214,000 | 4,023,000 | 911,000 | 3,809,000 | 2,981,000 | -182,000 | 4,525,000 | 1,582,000 | -2,193,000 | 727,000 | 3,703,000 | 361,000 | -156,000 | -251,000 | 717,000 | 168,000 |
Earnings Before Taxes | -37.7% | -43,583,000 | -31,660,000 | -24,705,000 | -40,517,000 | -53,219,000 | -70,079,000 | -29,263,000 | -61,246,000 | -81,451,000 | -80,296,000 | -50,476,000 | -46,700,000 | -64,082,000 | -73,594,000 | -63,284,000 | -48,789,000 | -88,587,000 | -89,885,000 | -62,060,000 | -83,834,000 | -120,131,000 |
EBT Margin | 11.8% | -0.33 | -0.38 | -0.51 | -0.55 | -0.63 | -0.74 | -0.78 | -0.85 | -0.81 | -0.79 | -0.80 | -0.88 | - | - | - | - | - | - | - | - | - |
Net Income | -43.1% | -48,419,000 | -33,843,000 | -21,577,000 | -43,232,000 | -52,932,000 | -55,865,000 | -33,286,000 | -62,157,000 | -85,260,000 | -83,277,000 | -50,294,000 | -51,225,000 | -65,664,000 | -71,401,000 | -64,011,000 | -52,492,000 | -88,948,000 | -89,729,000 | -61,809,000 | -84,551,000 | -120,299,000 |
Net Income Margin | 8.5% | -0.35 | -0.38 | -0.47 | -0.53 | -0.61 | -0.72 | -0.82 | -0.87 | -0.85 | -0.82 | -0.81 | -0.90 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -1924.3% | -31,506,000 | 1,727,000 | -39,912,000 | -18,335,000 | -20,011,000 | -83,449,000 | -11,489,000 | -16,217,000 | -59,186,000 | -72,274,000 | -24,590,000 | -36,289,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -7.2% | 722 | 778 | 764 | 730 | 701 | 724 | 760 | 801 | 827 | 905 | 957 | 787 | 810 | 887 | 901 | 701 | 738 | 850 | 882 | 918 | 765 |
Current Assets | -10.7% | 431 | 483 | 463 | 433 | 400 | 424 | 459 | 498 | 519 | 597 | 651 | 481 | 503 | 579 | 585 | 384 | 408 | 520 | 577 | 635 | 483 |
Cash Equivalents | -13.8% | 213 | 247 | 263 | 211 | 161 | 149 | 278 | 236 | 233 | 245 | 386 | 177 | 185 | 166 | 211 | 165 | 123 | 146 | 166 | 221 | 96.00 |
Inventory | 1.8% | 61.00 | 60.00 | 57.00 | 51.00 | 27.00 | 24.00 | 13.00 | 21.00 | 24.00 | 27.00 | 22.00 | 24.00 | 19.00 | 20.00 | 16.00 | 13.00 | 13.00 | 14.00 | 9.00 | 10.00 | 8.00 |
Net PPE | 2.4% | 32.00 | 32.00 | 31.00 | 30.00 | 31.00 | 31.00 | 32.00 | 34.00 | 35.00 | 42.00 | 42.00 | 42.00 | 43.00 | 44.00 | 45.00 | 47.00 | 48.00 | 48.00 | 35.00 | 15.00 | 13.00 |
Goodwill | 0% | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 |
Liabilities | -4.3% | 591 | 618 | 631 | 619 | 598 | 601 | 627 | 627 | 588 | 598 | 580 | 573 | 559 | 600 | 580 | 340 | 336 | 374 | 334 | 318 | 313 |
Current Liabilities | -15.3% | 142 | 168 | 169 | 159 | 138 | 139 | 165 | 165 | 130 | 146 | 121 | 112 | 100 | 130 | 112 | 108 | 92.00 | 129 | 93.00 | 90.00 | 66.00 |
Long Term Debt | 0.1% | 388 | 388 | 394 | 393 | 393 | 392 | 391 | 391 | 390 | 389 | 389 | 390 | 390 | 389 | 389 | - | - | 150 | - | - | - |
Shareholder's Equity | -18.4% | 131 | 160 | 133 | 112 | 103 | 123 | 133 | 173 | 239 | 307 | 377 | 214 | 251 | 286 | 320 | 361 | 403 | 476 | 548 | 600 | 452 |
Retained Earnings | -1.2% | -2,732 | -2,700 | -2,700 | -2,628 | -2,585 | -2,532 | -2,500 | -2,443 | -2,381 | -2,295 | -2,212 | -2,162 | -2,100 | -2,045 | -1,974 | -1,910 | -1,900 | -1,768 | -1,678 | -1,600 | -1,532 |
Additional Paid-In Capital | 0.6% | 2,854 | 2,836 | 2,787 | 2,733 | 2,692 | 2,665 | 2,645 | 2,631 | 2,618 | 2,595 | 2,580 | 2,364 | 2,351 | 2,309 | 2,275 | 2,251 | 2,238 | 2,227 | 2,211 | 2,201 | 1,971 |
Accumulated Depreciation | 4.5% | 27.00 | 25.00 | 25.00 | 24.00 | 23.00 | 22.00 | 23.00 | 22.00 | 21.00 | 20.00 | 19.00 | 17.00 | 16.00 | 14.00 | 24.00 | 21.00 | 19.00 | 18.00 | 18.00 | 17.00 | 16.00 |
Shares Outstanding | 0.9% | 296 | 294 | 291 | 287 | 283 | 281 | 289 | 292 | 288 | 271 | 266 | 265 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 3,557 | - | - | - | 2,980 | - | - | - | 2,541 | - | - | - | 3,851 | - | - | - | 3,147 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -958.7% | -29,695 | 3,458 | -38,347 | -16,133 | -18,069 | -80,772 | -11,626 | -15,862 | -58,315 | -70,514 | -23,700 | -35,923 | -72,354 | -49,822 | -42,008 | -33,518 | -107,942 | -57,832 | -55,553 | -58,485 | -78,546 |
Share Based Compensation | 70.2% | 30,803 | 18,095 | 16,511 | 16,577 | 34,894 | 18,626 | 14,772 | 12,463 | 30,651 | 13,907 | 11,841 | 11,736 | 20,354 | 12,239 | 15,908 | 8,408 | 12,596 | 12,908 | 8,843 | 9,935 | 12,744 |
Cashflow From Investing | 131.5% | 7,537 | -23,957 | 35,765 | 50,001 | 36,255 | -66,704 | 74,515 | 26,292 | 58,213 | -68,089 | 34,572 | 25,713 | 86,565 | -22,776 | -154,061 | 70,012 | 93,246 | 26,963 | 3,193 | -15,068 | 80,065 |
Cashflow From Financing | -262.1% | -13,309 | 8,210 | 37,619 | 23,673 | -7,825 | 557 | -559 | 693 | -8,154 | -104 | 201,113 | 2,235 | 8,829 | 21,548 | 238,711 | 4,086 | -1,487 | 3,191 | 523 | 196,404 | 17,384 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net product sales | $ 110,403 | $ 86,270 |
Cost of goods sold | 13,567 | 6,942 |
Gross profit | 96,836 | 79,328 |
Operating expenses: | ||
Research and development | 28,329 | 41,499 |
Selling, general, and administrative | 88,029 | 73,957 |
Changes in fair value of contingent consideration payable | 0 | 251 |
Restructuring charges | 6,045 | 0 |
Depreciation and amortization | 2,154 | 1,257 |
Total operating expenses | 124,557 | 116,964 |
Loss from operations | (27,721) | (37,636) |
Other expense: | ||
Interest income | 1,540 | 2,199 |
Interest expense | (12,436) | (11,844) |
Other expense | (4,966) | (5,938) |
Loss before income tax | (43,583) | (53,219) |
Income tax (expense) benefit | (4,836) | 287 |
Net loss attributable to common stockholders | $ (48,419) | $ (52,932) |
Net loss attributable to common stockholders per common share - basic (in dollars per share) | $ (0.16) | $ (0.18) |
Net loss attributable to common stockholders per common share — diluted (in dollars per share) | $ (0.16) | $ (0.18) |
Weighted average common shares outstanding - basic (in shares) | 302,903,009 | 291,336,750 |
Weighted average common shares outstanding - diluted (in shares) | 302,903,009 | 291,336,750 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 209,761 | $ 246,994 |
Investments in marketable securities | 29,842 | 39,206 |
Accounts receivable | 76,433 | 87,632 |
Inventories | 60,759 | 59,696 |
Prepaid expenses and other current assets | 54,444 | 49,533 |
Total current assets | 431,239 | 483,061 |
Operating lease right-of-use assets, net | 23,003 | 26,312 |
Property and equipment, less accumulated depreciation of $26,563 and $25,429 at March 31, 2024 and December 31, 2023, respectively | 32,421 | 31,667 |
Intangible assets, less accumulated amortization of $3,328 and $2,510 at March 31, 2024 and December 31, 2023, respectively | 19,672 | 20,490 |
Goodwill | 197,797 | 197,797 |
Other non-current assets | 17,657 | 18,553 |
Total Assets | 721,789 | 777,880 |
Current liabilities: | ||
Accounts payable | 9,210 | 15,120 |
Accrued expenses and other current liabilities | 124,622 | 144,245 |
Operating lease liabilities | 8,270 | 8,324 |
Total current liabilities | 142,102 | 167,689 |
Long-term debt | 388,391 | 387,858 |
Operating lease liabilities | 47,831 | 48,877 |
Other non-current liabilities | 12,771 | 13,282 |
Total liabilities | 591,095 | 617,706 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Common stock, $0.01 par value, 500,000,000 shares authorized, 296,159,417 and 293,594,209 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2,922 | 2,918 |
Additional paid-in capital | 2,853,550 | 2,836,018 |
Accumulated other comprehensive loss: | ||
Foreign currency translation adjustment | 6,847 | 5,429 |
Unrealized loss on available-for-sale securities | (203) | (188) |
Warrants | 71 | 71 |
Accumulated deficit | (2,732,493) | (2,684,074) |
Total stockholders’ equity | 130,694 | 160,174 |
Total Liabilities and Stockholders’ Equity | $ 721,789 | $ 777,880 |